Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 395

Similar articles for PubMed (Select 19897535)

1.

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (<pCR) after primary chemotherapy.

Ionta MT, Atzori F, Deidda MC, Pusceddu V, Palmeri S, Frau B, Murgia M, Barca M, Minerba L, Massidda B.

Oncologist. 2009 Nov;14(11):1051-60. doi: 10.1634/theoncologist.2009-0077. Epub 2009 Nov 6.

2.

Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer.

Touboul E, Buffat L, Lefranc JP, Blondon J, Deniaud E, Mammar H, Laugier A, Schlienger M.

Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):1019-28.

PMID:
8600084
3.

Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.

Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, Barbieri MR, Romero Acuña LA, Romero Acuña JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA.

Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31.

PMID:
9554929
4.

Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.

Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N.

Cancer. 2002 Aug 15;95(4):681-95.

5.

Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36.

PMID:
15380576
6.

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE.

J Clin Oncol. 1999 Feb;17(2):460-9.

PMID:
10080586
7.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
8.

[Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].

Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J.

Cancer Radiother. 2004 Jun;8(3):155-67. French.

PMID:
15217583
9.

Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.

Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E.

J Clin Oncol. 2002 Mar 1;20(5):1304-10.

PMID:
11870173
10.

Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.

Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE.

Am J Surg. 1998 Dec;176(6):502-9.

PMID:
9926779
11.

Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer.

Gülben K, Berberoğlu U, Cengiz A, Altinyollar H.

World J Surg. 2007 Sep;31(9):1724-30.

PMID:
17629742
12.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4.

13.

Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.

Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, van de Vijver MJ, Dalesio O, van Tinteren H, Rutgers EJ, Richelt DJ, Rodenhuis S.

Ann Oncol. 2002 May;13(5):689-98.

14.

The importance of extracapsular extension of axillary lymph node metastases in breast cancer.

Ilknur GB, Hilmi A, Tülay C, Oguz C, Selma S, Serdar S, Uğur Y, Pinar B, Omer H, Münir K; Dokuz Eylül University Medical Faculty Breast Tumors Study Group.

Tumori. 2004 Jan-Feb;90(1):107-11.

PMID:
15143982
15.

Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.

Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J.

Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1062-73.

PMID:
15234040
16.

Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer.

Adkins D, Brown R, Trinkaus K, Maziarz R, Luedke S, Freytes C, Needles B, Wienski D, Fracasso P, Pluard T, Moriconi W, Ryan T, Hoelzer K, Safdar S, Rearden T, Rodriguez G, Khoury H, Vij R, DiPersio J.

J Clin Oncol. 1999 Jul;17(7):2006-14.

PMID:
10561251
17.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

18.

Locally advanced breast cancer.

Sikov WM.

Curr Treat Options Oncol. 2000 Aug;1(3):228-38. Review.

PMID:
12057165
19.

[Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].

Guan Y, Xu BH, Li Q, Zhang P, Zhao LM, Yuan P, Wang JY.

Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):77-81. Chinese.

PMID:
18353207
20.

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.

Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M, Sacks N, McKinna J.

J Clin Oncol. 1998 Jan;16(1):107-14.

PMID:
9440730
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk